SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it introduced the cobas HDV test for use on the cobas 5800/6800/8800 systems, a diagnostic tool for the detection and quantification of Hepatitis D Virus RNA, in countries accepting the CE mark. The company noted that the cobas HDV test is the first high-throughput, fully automated HDV assay on the market.
Matt Sause, CEO of Roche Diagnostics, said: 'With the cobas HDV test, we are providing clinicians with a reliable tool to aid in the identification of infected individuals and to monitor their response to treatment.'
At last close, Roche shares were trading at 330.70 Swiss francs, down 1.75%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
